Article Information
History
- August 14, 2020.
Article Versions
- You are currently viewing Version 1 of this article (August 14, 2020 - 12:28).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- H Ward1,2,6,*,
- C Atchison1,2,
- M Whitaker1,
- KEC Ainslie1,3,
- J Elliott1,
- L Okell1,3,
- R Redd1,
- D Ashby1,
- CA Donnelly1,3,4,
- W Barclay2,5,
- A Darzi7,
- G Cooke2,5,6,
- S Riley1,3 and
- P Elliott1,2,6,8,*
- 1School of Public Health, Imperial College London
- 2Imperial College Healthcare NHS Trust
- 3MRC Centre for Global infectious Disease Analysis, School of Public Health, Imperial College London
- 4Department of Statistics, University of Oxford
- 5Department of Infectious Disease, Imperial College London
- 6National Institute for Health Research Imperial Biomedical Research Centre
- 7Institute of Global Health Innovation at Imperial College London
- 8MRC Centre for Environment and Health, School of Public Health, Imperial College London
- ↵*Corresponding authors Helen Ward h.ward{at}imperial.ac.uk, Paul Elliott p.elliott{at}imperial.ac.uk
Posted August 14, 2020.
Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults
